TORONTO and HAIFA, Israel, Aug. 13, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (“NurExone” or the “Company“) (TSXV: NRX, OTCQB: NRXBF, FSE: J90), a biotechnology company developing exosome-based regenerative therapies, today announced that its wholly owned U.S. subsidiary, Exo-Top Inc. (“Exo-Top“), together with the Company, has signed a binding memorandum of understanding (“MOU“) with Made Scientific, Inc. (“Made Scientific”) to establish an exclusive U.S. Good Manufacturing Practice (“GMP”) manufacturing and commercial exosome supply partnership to support NurExone’s clinical and commercial activities.
The proposed partnership brings together two companies with a shared vision for building scalable U.S. manufacturing infrastructure to support exosome-based therapeutics and commercial exosome products – two rapidly growing markets.
Made Scientific is a U.S.-based cell therapy contract development and manufacturing organization (“CDMO“) which operates a 60,000-square-foot U.S. FDA and EU GMP Annex 1 compliant facility in Princeton, New Jersey.
The parties intend to immediately begin the transfer of NurExone technology in parallel with negotiation of a definitive partnership agreement, with a target of initiating first GMP exosome batches in H1 2027.